A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

• Status: Recruiting
• Trial end date: 2022-12-24

Summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

• Phase: Phase 2

Details

• Lead Sponsor: Hoffmann-La Roche